Skip to main content
. 2014 Apr 23;45(1):439–447. doi: 10.3892/ijo.2014.2396

Figure 4.

Figure 4.

ATN-224 in aggressive lymphomas. (A) JC-1 aggregates (ΔΨm) in U-2932 and Granta 519 cells treated with vehicle or ATN-224 (EC50) for 12 h. (B) Immunoblots showing Mcl-1, Bcl-2 and Bcl-xL protein levels in U-2932 and Granta 519 cells treated with vehicle or ATN-224 (EC50) for 24 and 48 h. Immunoblots showing actin protein levels to demonstrate similar loading. (C) Immunoblots showing Bak, Bax, Bim, Noxa and Bid protein levels in U-2932 and Grants 519 cells with the same treatments as in (B). All immunoblots are representative blots from three independent sample collections. (D) Caspase 3 activity measured in U-2932 and Granta 519 cells treated with vehicle or ATN-224 (EC50) for 24 h. (E) Cell viability (PI uptake) in U-2932 and Granta 519 cells treated with vehicle, 25 μM ZVAD-FMK (ZVAD), ATN-224 (EC50) or a combination of ZVAD-FMK and ATN-224 for 72 h. All values are mean ± SEM (n ≥3). *p≤0.05, significantly different from vehicle treated control cells.